INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 179 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,321,652 | -26.9% | 19,297 | -26.1% | 0.00% | 0.0% |
| Q1 2024 | $1,807,296 | +6.9% | 26,117 | +10.7% | 0.00% | 0.0% |
| Q4 2023 | $1,690,232 | +163682.2% | 23,600 | +28.2% | 0.00% | -50.0% |
| Q1 2023 | $1,032 | +93.3% | 18,402 | +82.2% | 0.00% | +100.0% |
| Q4 2022 | $534 | -99.9% | 10,100 | -53.9% | 0.00% | -50.0% |
| Q3 2022 | $991,000 | +58.1% | 21,900 | +110.6% | 0.00% | – |
| Q1 2022 | $627,000 | -72.6% | 10,400 | -76.3% | 0.00% | -100.0% |
| Q4 2021 | $2,291,000 | +118.4% | 43,945 | +50.0% | 0.00% | +100.0% |
| Q3 2021 | $1,049,000 | +326.4% | 29,290 | +372.4% | 0.00% | – |
| Q2 2021 | $246,000 | -71.3% | 6,200 | -76.7% | 0.00% | -100.0% |
| Q4 2020 | $857,000 | -40.0% | 26,600 | -52.5% | 0.00% | -50.0% |
| Q3 2020 | $1,429,000 | -4.7% | 55,956 | -6.0% | 0.00% | 0.0% |
| Q2 2020 | $1,499,000 | +87.4% | 59,546 | +17.7% | 0.00% | +33.3% |
| Q1 2020 | $800,000 | -90.9% | 50,600 | -80.7% | 0.00% | -85.7% |
| Q4 2019 | $8,820,000 | +1423.3% | 262,035 | +239.4% | 0.02% | +950.0% |
| Q3 2019 | $579,000 | -59.1% | 77,200 | -29.3% | 0.00% | -60.0% |
| Q2 2019 | $1,417,000 | -15.9% | 109,216 | -21.0% | 0.01% | -16.7% |
| Q1 2019 | $1,685,000 | +76.1% | 138,300 | +62.9% | 0.01% | +100.0% |
| Q4 2018 | $957,000 | -71.9% | 84,924 | -45.9% | 0.00% | -62.5% |
| Q3 2018 | $3,405,000 | +47.0% | 156,902 | +42.5% | 0.01% | +33.3% |
| Q2 2018 | $2,316,000 | 0.0% | 110,069 | 0.0% | 0.01% | 0.0% |
| Q1 2018 | $2,316,000 | +149.8% | 110,069 | +71.9% | 0.01% | +50.0% |
| Q4 2017 | $927,000 | +8.0% | 64,014 | +17.7% | 0.00% | 0.0% |
| Q3 2017 | $858,000 | +115.0% | 54,400 | +72.7% | 0.00% | +100.0% |
| Q2 2017 | $399,000 | -51.9% | 31,500 | -38.2% | 0.00% | -50.0% |
| Q1 2017 | $829,000 | +25.8% | 51,000 | +16.7% | 0.00% | +33.3% |
| Q4 2016 | $659,000 | -66.4% | 43,700 | -65.7% | 0.00% | -66.7% |
| Q3 2016 | $1,963,000 | -37.7% | 127,306 | +51.2% | 0.01% | -47.1% |
| Q2 2016 | $3,152,000 | – | 84,200 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
| Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
| Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
| Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
| Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
| GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
| Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
| WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |